Skip to main content
. 2016 Oct 8;7(48):78605–78618. doi: 10.18632/oncotarget.12522

Figure 2. CCL27 rescues myeloma cells from treatment with proteasome inhibitors in the presence of stroma.

Figure 2

(A) Cocultures of myeloma cells and HS-5 stroma cells (ratio 2:1) were treated for 48 hrs with different concentrations of bortezomib (2.6/5.2/7.8 nM) with and without CCL27 (7.9 nM) and CCL28 (8.1 nM) (n > 3). Percentage of viable myeloma cells (Ann-V/7-AAD negativ) compared to untreated control is shown in all graphs in this figure. **p < 0.01; (B) Myeloma cell lines were cocultured on primary stroma cells isolated from myeloma bone marrow aspirates of 3 patients, treated as above (bortezomib 5.2 nM) and viability of myeloma cells was measured. (C) Similar, primary myeloma cells (CD138-sorted) from 4 different patients were cocultured with HS-5 stroma cell line, treated as above (bortezomib 7.8 nM) and their viability was measured; assays were performed in duplicates for (B) and (C).